Non-Invasive Prenatal Testing Market Worldwide Industry Analysis

ALISO VIEJO, Calif. - Jan. 27, 2020 - PRLog -- The market is growing due to the rising incidence of chromosome syndromes, healthcare expenditures, average maternal age, and demand for early and non-invasive fetal testing procedures. The screening method for the detection of specific chromosomal abnormalities in a developing baby, from as early as week 10 of the pregnancy, is called non-invasive prenatal testing.

On the basis of test type, the NIPT market (https://www.psmarketresearch.com/market-analysis/non-invasive-prenatal-testing-market) is divided into NIFTY, Verifi, PrenaTest, MaterniT21 PLUS, Harmony, Panorama, and others. Out of these, MaterniT21 PLUS held the largest share of the market in 2014 and is predicted to hold 26.0% market share in 2020. This test was developed by Sequenom Laboratories for detecting fetal chromosomal abnormalities, including Trisomy 21, Trisomy 16, and Trisomy 22, and selected microdeletions, including 4p (Wolf-Hirschhorn syndrome) and 11q (Jacobsen syndrome). The fastest CAGR is expected to be witnessed by NIFTY during the forecast period.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/non-invasive-prenatal-testing-market/report-sample

Another factor contributing to the growth of the NIPT market is the increasing incidence rate of chromosome syndromes. Chromosome syndromes lead to miscarriage and congenital birth defects. Some common chromosomal syndromes are Trisomy 18 (Edward syndrome), 45, X (Turner syndrome), Trisomy 21 (Down syndrome), Trisomy 13 (Patau syndrome), and 47, XXX (Klinefelter syndrome). As per the World Health Organization, about 3,000 to 5,000 children every year are born with chromosome disorder.

The growing demand for early and non-invasive prenatal testing procedures is also driving the NIPT market significantly. Prenatal tests are performed during pregnancy for determining the development of fetus. Different diagnostic techniques, such as urine test, ultrasound, and blood test help determine the characteristics of the baby, including age, size, sex, placement in the uterus, and the chance of it having any genetic problems or birth defects. This demand for non-invasive and early fetal testing procedures is rising primarily due to the growing awareness regarding birth defects.

Hence, the market is growing due to the rising requirement for early and non-invasive testing procedures, incidence rate of chromosome syndrome, and average maternal age.